CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) shares traded up 9% during trading on Monday . The company traded as high as $3.82 and last traded at $3.86, 19,355 shares changed hands during trading. A decline of 91% from the average session volume of 212,982 shares. The stock had previously closed at $3.54.
A number of research firms have weighed in on CANF. Zacks Investment Research lowered CAN-FITE BIOPHA/S from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. HC Wainwright reiterated a “positive” rating and set a $5.00 price objective (up previously from $3.00) on shares of CAN-FITE BIOPHA/S in a research note on Thursday, October 31st.
CAN-FITE BIOPHA/S (NYSEAMERICAN:CANF) last posted its quarterly earnings data on Friday, August 30th. The biotechnology company reported ($1.20) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.80) by ($0.40). The company had revenue of $0.39 million during the quarter.
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of autoimmune-inflammatory, oncological, and liver diseases. The company's lead drug candidate is CF101 (Piclidenoson), which is in Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis.
See Also: How to invest in blue-chip stocks
Receive News & Ratings for CAN-FITE BIOPHA/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CAN-FITE BIOPHA/S and related companies with MarketBeat.com's FREE daily email newsletter.